医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2013年
18期
102-102,103
,共2页
NP方案%GP方案%晚期非小细胞肺癌%Meta分析
NP方案%GP方案%晚期非小細胞肺癌%Meta分析
NP방안%GP방안%만기비소세포폐암%Meta분석
NP schemes%GP schemes%Adcvanced non-smal cel lung cancer%Meta analysis
目的采用Meta分析比较NP和GP方案治疗晚期非小细胞肺癌在有效率和骨髓抑制方面的优缺点。方法检索有关NP和GP方案治疗晚期非小细胞肺癌的临床对比研究,分别对入选的研究进行文献评价,进行Meta分析。结果从1994年~2005年共有12个研究入选,实验组413例。对照组共401例。分析结果显示：有效率RR值为1.05,95%可信区间为0.90~1.23,总体效应检验Z=0.63,P>0.05,无统计学意义；白细胞下降RR值为1.43,95%可信区间为1.26~1.61,总体效应检验Z=5.58,P<0.05,有统计学意义；血小板下降RR值为0.83,95%可信区间为0.72~0.96,总体效应检验Z=2.44,P<0.05,有统计学意义。结论 NP和GP方案均为治疗晚期非小细胞肺癌的有效方案。 GP方案对白细胞的影响小而对血小板的影响大。敏感性分析和发表性偏倚的识别结果表明,本次Meta分析的结果稳定,可靠。
目的採用Meta分析比較NP和GP方案治療晚期非小細胞肺癌在有效率和骨髓抑製方麵的優缺點。方法檢索有關NP和GP方案治療晚期非小細胞肺癌的臨床對比研究,分彆對入選的研究進行文獻評價,進行Meta分析。結果從1994年~2005年共有12箇研究入選,實驗組413例。對照組共401例。分析結果顯示：有效率RR值為1.05,95%可信區間為0.90~1.23,總體效應檢驗Z=0.63,P>0.05,無統計學意義；白細胞下降RR值為1.43,95%可信區間為1.26~1.61,總體效應檢驗Z=5.58,P<0.05,有統計學意義；血小闆下降RR值為0.83,95%可信區間為0.72~0.96,總體效應檢驗Z=2.44,P<0.05,有統計學意義。結論 NP和GP方案均為治療晚期非小細胞肺癌的有效方案。 GP方案對白細胞的影響小而對血小闆的影響大。敏感性分析和髮錶性偏倚的識彆結果錶明,本次Meta分析的結果穩定,可靠。
목적채용Meta분석비교NP화GP방안치료만기비소세포폐암재유효솔화골수억제방면적우결점。방법검색유관NP화GP방안치료만기비소세포폐암적림상대비연구,분별대입선적연구진행문헌평개,진행Meta분석。결과종1994년~2005년공유12개연구입선,실험조413례。대조조공401례。분석결과현시：유효솔RR치위1.05,95%가신구간위0.90~1.23,총체효응검험Z=0.63,P>0.05,무통계학의의；백세포하강RR치위1.43,95%가신구간위1.26~1.61,총체효응검험Z=5.58,P<0.05,유통계학의의；혈소판하강RR치위0.83,95%가신구간위0.72~0.96,총체효응검험Z=2.44,P<0.05,유통계학의의。결론 NP화GP방안균위치료만기비소세포폐암적유효방안。 GP방안대백세포적영향소이대혈소판적영향대。민감성분석화발표성편의적식별결과표명,본차Meta분석적결과은정,가고。
Objective:To investigate the ef ective rate and arrest of bone marrow (decrease of leucocytes, plate-let) ofneoadjuvant chemotherapy schemes NP and GP in the therapy of advanced non- smal cel lung cancer by Meta analysis. Methods:After general y col ection the clinical literatures published in domestic and overseas from1994 to 2005 that reported on the ef ective rate and arrestofbonemarro (decrease of leukocyte, platelet) ofneoad-juvant chemotherapy schemesNP andGP in the therapy ofadvanced non-smal cel lung cancer, Meta analysiswas performed are processed by Review Manager 4. 2 program, selecting fixed or random modelbased on the heterogeneity test. Results:1From 1994 to 2005 a total of 12 studies were selected, the experimental group 413 cases. A total of 401 cases of the control group. The results show:The ef ective RR was 1.05, 95%CI 0.90-1.23, test for overal ef ect Z=0. 63, P>0. 05, no statistical y significant;leukopenia RR value of 1.43, 95%CI 1.26-1.61, test for overal ef ect Z=5. 58, P<0. 05, there was significant;thrombocytopenia RR was 0.83, 95%CI 0.72~0.96, test for overal ef ect Z=2. 44, P<0. 05, was statistical y significant. Conclusion:NP and GP schemes are ef ective in therapy ofnon- smal cel lung cancer.Decrease of leukocyte and platelet are two adverse ef ects. Decrease of leukocyte is greater in NP schemes, decrease of platelet is greater in GP schemes.
